Veru (VERU) Non-Current Deffered Revenue (2010 - 2019)
Veru (VERU) posted quarterly Non-Current Deffered Revenue of $201167.0 for Q2 2019, up 125.79% year-over-year from $89093.0 in Q2 2018, and down 4.48% quarter-over-quarter from $210594.0 in Q1 2019.
Veru (VERU) Non-Current Deffered Revenue (2010 - 2019) Analysis & Trends
Veru (VERU) has reported Non-Current Deffered Revenue for 10 consecutive years, with $201167.0 the latest figure, recorded in Q2 2019.
- In Q2 2019, Non-Current Deffered Revenue rose 125.79% year-over-year to $201167.0; the TTM figure through Jun 2019 stood at $201167.0 (up 125.79% YoY), while the FY2018 annual figure was $86328.0, changed N/A from the prior year.
- Non-Current Deffered Revenue declined to $201167.0 in Q2 2019 per VERU's latest filing, from $210594.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $210594.0 in Q1 2019 and bottomed at $4801.0 in Q2 2016.
- Historically, Non-Current Deffered Revenue has averaged $68772.9 across 5 years, with a median of $61442.0 in 2017.
- Annual changes were most pronounced in 2016 — Non-Current Deffered Revenue sank 73.84% — and 2017, when it surged 1179.78%.
- Veru's Non-Current Deffered Revenue stood at $12001.0 in 2015, then surged by 86.85% to $22424.0 in 2016, then surged by 205.24% to $68446.0 in 2017, then climbed by 26.13% to $86328.0 in 2018, then soared by 133.03% to $201167.0 in 2019.
- Business Quant data shows VERU's Non-Current Deffered Revenue at $201167.0 in Q2 2019, $210594.0 in Q1 2019, and $86328.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 201,167.00 |
| Mar 31, 2019 | 210,594.00 |
| Dec 31, 2018 | 86,328.00 |
| Sep 30, 2018 | 88,161.00 |
| Jun 30, 2018 | 89,093.00 |
| Mar 31, 2018 | 81,192.00 |
| Dec 31, 2017 | 68,446.00 |
| Sep 30, 2017 | 131,830.00 |
| Jun 30, 2017 | 61,442.00 |
| Mar 31, 2017 | 44,850.00 |
| Dec 31, 2016 | 22,424.00 |
| Jun 30, 2016 | 4,801.00 |
| Mar 31, 2016 | 8,401.00 |
| Dec 31, 2015 | 12,001.00 |
| Sep 30, 2015 | 15,389.00 |
| Jun 30, 2015 | 18,352.00 |
| Mar 31, 2015 | 24,669.00 |
| Dec 31, 2014 | 31,899.00 |
| Sep 30, 2014 | 39,105.00 |
| Jun 30, 2014 | 46,133.00 |